# Presentation: 354153

## Influenza Vaccine Responses 

**Roland A. Levandowski, M.D.**
**Division of Viral Products**

**Prepared for **
**Vaccines and Related Biological **
**Products Advisory Committee**
**18-19 February 2004**

## Serum Panels for Serologies

** **
**1. ****	****ALAN HAMPSON****	****ADULT****	****A/NEW CALEDONIA/20/99-LIKE  (H1N1)**
**	****WHO, AUSTRALIA****	****ELDER****	****A/PANAMA/2007/99  (H3N2) **
**	****	****	****	****	****B/SHANGDONG/07/97**
** **
**2. ****	****JOHN WOOD, PH.D****	****ADULT****	****A/NEW CALEDONIA/20/99  (H1N1) **
**	****NIBSC, ENGLAND****	****ELDER****	****A/PANAMA/2007/99  (H3N2) **
**	****	****	****	****	****B/SHANGDONG/7/97**
** **
**3. TAKATO ODIGARI, PH.D. ****	****ADULT****	****A/NEW CALEDONIA/20/99-LIKE  (H1N1) **
**	****WHO, JAPAN****	****	****ELDER****	****A/PANAMA/2007/99-LIKE  (H3N2) **
**	****	****	****	****	****B/HONG KONG/330/01-LIKE**
** **
**	****	****	****	**

## Serum Panels for Serologies

** ****	**** **
**4. ****	****STEFAN GRAVENSTEIN, M.D.****	****ADULT****	****A/NEW CALEDONIA/20/99 (H1N1) **
**	****EASTERN VIRGINIA ****	****	****ELDER****	****A/PANAMA/2007/99 (H3N2)**
**	****MEDICAL SCHOOL****	****	****CHILD****	****B/HONG KONG/1434/2002****	**
** **
**5.****	****CHRISTINE TURLEY, M.D.****	****CHILD****	****A/NEW CALEDONIA/20/99 (H1N1)**
**	****UTMB ****	****	****	****	****A/PANAMA/2007/99 (H3N2)**
**	****GALVESTON, TEXAS****	****	****	****B/HONG KONG/1434/2002 **
** ****6.****	****STEFAN GRAVENSTEIN, M.D.****	****ADULT****	****B/VICTORIA/504/2000****	****	**** ****	****	****	****ELDER**** ****	****(VACCINE USED IN 2001-02)**
**7.****	****JOHN WOOD, PH.D   ****	****	****ADULT****	****B/JOHANNESBURG/5/99**
**	****	****	****	****	****	****(VACCINE USED IN 2001-02)**
**	****	****	****	**

## ANTIGENS FOR SEROLOGIES (H1)

**VACCINE STRAIN**
**	****A/NEW CALEDONIA/20/99 (H1N1)**
**REPRESENTATIVE CURRENT STRAINS**
**	****A/DAKAR/85/2003 (H1N1)**
**	****A/MINNESOTA/18/2003 (H1N1)**
**	****A/NAGANO/1328/2003 (H1N1)**
**	****A/BELEM/84066/03 (H1N2)**
**	****A/ICELAND/123/2003 (H1N2)**
**	****A/PERU/2223/2003 (H1N2)**
**	****A/VIRGINIA/20/03 (H1N2)**

## HI ANTIBODY RESPONSES TO THE H1 COMPONENT2003-2004 INFLUENZA VACCINEADULT POPULATION (CDC)

## HI ANTIBODY RESPONSES TO THE H1 COMPONENT2003-2004 INFLUENZA VACCINEELDERLY POPULATION (NIBSC)

## HI ANTIBODY RESPONSES TO THE H1 COMPONENT2003-2004 INFLUENZA VACCINEPEDIATRIC POPULATION (CDC AND CBER)

## A/NEW CALEDONIA/20/99-LIKE VACCINESSUMMARY TABLEVIRUSES WITH > 50% GMT REDUCTION

## ANTIGENS FOR SEROLOGIES (H3)

**VACCINE STRAIN**
**	****A/PANAMA/2007/99**
**REPRESENTATIVE CURRENT STRAINS**
**	****A/CHILE/82660/2003**
**	****A/AICHI/205/2003***
**	****A/KUMAMOTO/102/2002***
**	****A/FUJIAN/445/2003***
**	****A/NAGASAKI/152/2003*****	****	***** = FUJIAN/411-LIKE**
**	****A/TEXAS/40/2003***
**	****A/TEXAS/141/2003***
**	****A/WYOMING/03/2003***
**	****A/HONG KONG/1186/2002***

## HI ANTIBODY RESPONSES TO THE H3 COMPONENT2003-2004 INFLUENZA VACCINEADULT POPULATION ( AUS )

## HI ANTIBODY RESPONSES TO THE H3 COMPONENT2003-2004 INFLUENZA VACCINEELDERLY POPULATION (CDC)

## HI ANTIBODY RESPONSES TO THE H3 COMPONENT2003-2004 INFLUENZA VACCINEPEDIATRIC POPULATION (CDC AND CBER)

## A/PANAMA/2007/99-LIKE VACCINESSUMMARY TABLEVIRUSES WITH > 50% GMT REDUCTION

## ANTIGENS FOR SEROLOGIES (B)

**VACCINE STRAIN**
**	****CURRENT VACCINE****	****   OLDER VACCINE**
**	****B/SHANGDONG/7/97+****	****	****    B/JOHANNESBURG/5/99**
**	****B/HONG KONG/1434/2002+****	****    B/VICTORIA/504/2000**
**REPRESENTATIVE CURRENT STRAINS**
**	****B/SICHUAN/259/2003+**
**	****B/BADEN-WURTENBURG/26/2002***
**	****B/SHAHGHAI/361/2002***
**	****B/JIANGSU/10/2003*****	****	****+ = HONG KONG/330-LIKE**
**	****B/JILIN/20/2003*****	****	****	***** = SHANGHAI/361-LIKE**
**	****B/MALAYSIA/879/2003***
**	****B/WASHINGTON/3/2003***

## HI ANTIBODY RESPONSES TO THE B COMPONENT2003-2004 INFLUENZA VACCINEADULT POPULATION (NIBSC)

## HI ANTIBODY RESPONSES TO THE B COMPONENT2003-2004 INFLUENZA VACCINEELDERLY POPULATION (CDC)

## HI ANTIBODY RESPONSES TO THE B COMPONENT2003-2004 INFLUENZA VACCINEPEDIATRIC POPULATION (CDC AND CBER)

## HI ANTIBODY RESPONSES TO THE B COMPONENT2001-2002 INFLUENZA VACCINEADULT AND ELDERLY (NIBSC AND CBER)

## B/HONG KONG/330/2001-LIKE VACCINESSUMMARY TABLEVIRUSES WITH > 50% GMT REDUCTION

## Influenza Vaccine ResponsesSummary

- Studies with sera collected after immunization with current vaccines show that:
- Representative influenza A (H1N1) and (H1N2) viruses are well-inhibited
- Many a/Fujian/411/2002 (H3N2)-like viruses are less well inhibited than the the vaccine strain
- B/Hong Kong/330/2001-like viruses are well inhibited but B/Shanghai/361/2002 and similar viruses are less well inhibited than the vaccine strains